Tweets
Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS
Links:
Richard Conway @RichardPAConway ( View Tweet )
4 years 1 month ago
Pedersen et al report 6-fold mortality⬆️over 10 years in RA patients with co-existent depression. Even stronger effect in younger patients (<55) @RheumNow #EULAR2022 OP0067 https://t.co/vYYTmTnstQ https://t.co/xKgMu7zaOA
Links:
Richard Conway @RichardPAConway ( View Tweet )
4 years 1 month ago
NORD-STAR TRIAL drug does better in ttmt naive eRA? 48wks
CDAI remission ▶️ w/ ABA and CERTO PEG vs. MTX+ GCs while TCZ not stat ▶️.
Is the difference clinically sufficient to recommend these in first intention over MTX ? not convinced 🧐
OP0058 #EULAR22
@rheumnow
Aurelie Najm @AurelieRheumo ( View Tweet )
4 years 1 month ago
#EULAR OP0067
Incident depression is critical RA co-morbidity!
🚨>6x risk of death in 10 year follow-up🚨
Depression defined as 1st filling of anti-depressants
▶️Bias likely contributes, esp including neuropathic medications such as duloxetine, but data is staggering
@RheumNow https://t.co/xpQPDLonLj
Eric Dein @ericdeinmd ( View Tweet )
4 years 1 month ago
Screen for depression in RA patients!
From the #DANBIO registry of 11,000 pts, they found
6X ⬆️mortality in pts w/#RA and #depression . The mortality curve separates early. #Plenary OP0067 @rheumnow #EULAR2022 https://t.co/qfjyejGVzQ
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 1 month ago
Damien et al on Whipple's Disease presenting as RMD. 73 cases (wow!) Treat Whipples, 93% remission, 94% off DMARD @RheumNow #EULAR2022 OP0066 https://t.co/XQnQq4RNcq
Links:
Richard Conway @RichardPAConway ( View Tweet )
4 years 1 month ago
#EULAR2022 POS0241 shows JAKi ⬇️ pain catastrophization/central sensitization in RA patient via CSI (Central Sensitization Inventory) and (PCS) Pain Catastrophizing Scale.
No decrease of articular inflammation on ultrasound with JAKi shown, but study had just 22 pts
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
4 years 1 month ago
Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%).
#EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 1 month ago
Sustained benefits #voclosporin in #LupusNephritis AURORA2 - 2 year study POS0186:
👉no unexpected AEs; rate of AEs⬇️over time
👉COVID19 seen in 12 controls, 7 VCS
👉4 deaths w/control arm vs 0 deaths w/ VCS
👉GFR & sCr & reduction in UPCR remained stable #EULAR2022 @rheumnow
TheDaoIndex @KDAO2011 ( View Tweet )
4 years 1 month ago
10 year study showed NSAIDs associated with slowing radiographic progression in axSpA patients. mSASSS progression numerically lower in COX2i pts compared to non-selective NSAIDs.
@RheumNow #EULAR2022 #ABSTOP0021 https://t.co/dfz3rseikl
Robert B Chao, MD @doctorRBC ( View Tweet )
4 years 1 month ago
#EULAR2022 OP0066
French retrospective obs study 2019-2021 with 73 cases of Whipples disease treated for rheum disease
▶️M/F ratio 3, middle aged
▶️1/2 met RA criteria
▶️Peripheral jts, 1/3 had axial involvement
▶️Rx: HCQ, Doxi - 80% cured, DMARD stopped in >90% cases
@RheumNow https://t.co/t7zlDrPfJB
Eric Dein @ericdeinmd ( View Tweet )
4 years 1 month ago
NORD-STAR results. Biologic + MTX combo seemed better than slightly strange "conventional"(ACT) group of MTX + oral steroids or triple therapy + IA injections @RheumNow #EULAR2022 OP0058 https://t.co/tOfTlcplFR https://t.co/CvtvuVn5Xj
Links:
Richard Conway @RichardPAConway ( View Tweet )
4 years 1 month ago
